Hypofractionated radiation therapy for endometrial and cervical cancers
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers (HERA Trial)
This study is testing a new way of giving radiation therapy in larger doses over 5 days to see if it helps people who have had surgery for endometrial or cervical cancer feel better while making treatment easier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06538337 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of hypo-fractionated external beam radiotherapy with adaptive planning for patients who have undergone surgery for endometrial or cervical cancer. The approach involves delivering a total of 30 Gy in 5 larger doses, utilizing MRI or CT guidance to enhance treatment precision and tolerability. Participants will receive treatment over a span of 5 days, followed by regular follow-up appointments for up to 5 years to monitor outcomes and side effects. The goal is to determine if this method can reduce treatment burden while maintaining effectiveness.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed endometrial or cervical cancer who have undergone surgical resection and meet specific FIGO staging criteria.
Not a fit: Patients who are undergoing concurrent chemotherapy or have a history of prior irradiation to the treatment area may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to fewer radiation sessions with comparable side effects, improving patient comfort and treatment adherence.
How similar studies have performed: Previous studies have shown that adaptive planning in radiation therapy can significantly improve treatment outcomes, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed endometrial or cervical cancer * Surgical resection of the primary tumor * International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IVB endometrial cancer OR FIGO Stage IA-IIA cervical cancer that meets indications for receiving adjuvant pelvic radiotherapy alone as standard of care * Age ≥ 18 years old * Karnofsky performance status (KPS) ≥ 60 or Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * Must not meet indications for receiving concurrent chemotherapy as standard of care * Active treatment of a separate malignancy * History of prior irradiation to the area to be treated
Where this trial is running
Los Angeles, California
- University of California at Los Angeles — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Puja S. Venkat, MD — University of California at Los Angeles
- Study coordinator: Christy Palodichuk
- Email: cpalodichuk@mednet.ucla.edu
- Phone: 310-794-2971
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.